Search
Aptevo Therapeutics Inc
APVOAdd to Watchlist
4.470USD
+0.020+0.45%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
4.46MMarket Cap
0.00P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.45%
5 Days
-1.76%
1 Month
-12.01%
6 Months
-52.40%
Year to Date
-52.60%
1 Year
+47.04%
Key Figures
4.340Open
4.580High
18.77KVolume
0.00P/E TTM
LossP/E Dynamic
--Dividend TTM
1.88%Turnover Ratio
4.450Prev. Close
4.340Low
62.28KTurnover
LossP/E Static
0.26P/B
0.00%Div Yield TTM
-185.92%ROA
235.97852wk High
0.85Volume Ratio
-24.13MNet Profit
997.83KShares
1488.0455EPS TTM
1.69Beta
-550.82%ROE
3.80052wk Low
5.39%Amplitude
180.28%Gross Margin
4.46MMarket Cap
-2.43Reward/Risk
5.11%Risk Rate
TradingKey Stock Score of Aptevo Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Aptevo Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 203 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 25.50.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Aptevo Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Aptevo Therapeutics Inc Highlights
StrengthsRisks
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is 0.00, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 55.65K shares, increasing 23.12% quarter-over-quarter.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
25.500
Target Price
+473.03%
Upside Space
Aptevo Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Aptevo Therapeutics Inc Info
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.
Ticker SymbolAPVO
CompanyAptevo Therapeutics Inc
CEOWhite (Marvin L)
Websitehttps://aptevotherapeutics.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Aptevo Therapeutics Inc (APVO)?
The current price of Aptevo Therapeutics Inc (APVO) is 4.47.
What is the symbol of Aptevo Therapeutics Inc?
The ticker symbol of Aptevo Therapeutics Inc is APVO.
What is the 52-week high of Aptevo Therapeutics Inc?
The 52-week high of Aptevo Therapeutics Inc is 235.98.
What is the 52-week low of Aptevo Therapeutics Inc?
The 52-week low of Aptevo Therapeutics Inc is 3.80.
What is the market capitalization of Aptevo Therapeutics Inc?
The market capitalization of Aptevo Therapeutics Inc is 4.46M.
Is Aptevo Therapeutics Inc (APVO) currently rated as Buy, Hold, or Sell?
According to analysts, Aptevo Therapeutics Inc (APVO) has an overall rating of Buy, with a price target of 25.50.
What is the Earnings Per Share (EPS TTM) of Aptevo Therapeutics Inc (APVO)?
The Earnings Per Share (EPS TTM) of Aptevo Therapeutics Inc (APVO) is -87.27.